TheraCryf PLC

TCF

Company Profile

  • Business description

    TheraCryf PLC is a clinical-stage biotechnology company focused on profitable segments in oncology and neuropsychiatry. The company's lead clinical asset, SFX-01 is a patented form of delivering sulforaphane, which could be used in the treatment of a number of cancers, neurodevelopmental disorders, and other diseases.

  • Contact

    Congleton Road
    Alderley Park
    Nether AlderleyCheshireSK10 4TG
    GBR

    T: +44 1625315090

    E: [email protected]

    https://www.evgen.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 March 2026

    Employees

    9

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,133.106.200.08%
CAC 407,807.0069.36-0.88%
DAX 4022,186.10353.88-1.57%
Dow JONES (US)41,989.9611.80-0.03%
FTSE 1008,577.2257.58-0.67%
HKSE23,202.534.31-0.02%
NASDAQ17,449.89150.600.87%
Nikkei 22535,725.87101.390.28%
NZX 50 Index12,320.197.590.06%
S&P 5005,633.070.000.00%
S&P/ASX 2007,934.509.300.12%
SSE Composite Index3,350.131.690.05%

Market Movers